BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 3
• 4
• 5
• 7
• 8
• 9
• 10
• 11
• 12
• 14
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30

• Press Releases

  Oxford BioTherapeutics’ Third Partnered Programme with Boehringer Ingelheim Enters the Clinic and its First (Obrixtamig) Advances to Phase 3

  June 22, 2026

   · 

  6 min read
• Press Releases

  Pheno Therapeutics Granted FDA IND Clearance for Lead Multiple Sclerosis Therapeutic Candidate PTD802

  June 22, 2026

   · 

  2 min read
• Press Releases

  ChemDiv, Inc. Highlights Successful Deployment of Proprietary CNS Drug Discovery Platform, Advancing Neurodegenerative Programs for Polku Therapeutics and Brenig Therapeutics

  June 22, 2026

   · 

  2 min read
• Press Releases

  Innogen Pharmaceutical Group Highlights China-Originated Innovation and Global Development Strategy at DIA Global Annual Meeting 2026 China Town Hall

  June 22, 2026

   · 

  6 min read
• 

  Mergers & acquisitions

  AbbVie strikes $10.9B Apogee buy to challenge juggernaut Dupixent

  AbbVie will add Apogee’s IL-13 blocker to its current immunology stalwarts Skyrizi and Rinvoq, which have helped the pharma ride out the steep patent cliff left behind from mega-blockbuster drug Humira.

  June 22, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - June 22, 2026

  June 22, 2026

   · 

  4 min read
• Press Releases

  Nura Bio Completes $73.8M Series B Financing and Advances Pipeline of SARM1 Inhibitors

  June 22, 2026

   · 

  3 min read
• Press Releases

  Karmanos Cancer Institute Reaches Historic Growth Milestone, Positioning Itself as a Leader in Oncology Care Delivery

  June 22, 2026

   · 

  7 min read
• Press Releases

  Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

  June 22, 2026

   · 

  7 min read
• 

  Neuroscience

  Lilly bets up to $800M for BioArctic’s brain delivery tech

  Eli Lilly plans to use BioArctic’s technology to shuttle an undisclosed drug candidate into the brain. The pharma hasn’t specified which neurodegenerative disease it will target.

  June 22, 2026

   · 

  2 min read

   · 

  Tristan Manalac